-- 加拿大皇家银行资本市场(RBC Capital Markets)周日发布的一份报告指出,美伊核谈判再次陷入僵局,伊朗威胁封锁霍尔木兹海峡,这给全球石油供应和市场稳定带来了新的风险。 谈判破裂的原因是华盛顿坚持伊朗不进行铀浓缩,这进一步印证了加拿大皇家银行的观点,即如果没有让步,达成协议的可能性不大,而且冲突长期持续和供应中断的可能性也随之增加。 报告称,随着外交努力受挫,白宫面临着两种选择:要么退让,允许伊朗对霍尔木兹海峡拥有更大的控制权;要么升级军事行动,以对抗德黑兰对过境运输的影响力。 分析师在报告中指出,特朗普总统发出封锁警告表明他不愿让步,并可能试图通过威胁切断伊朗原油对中国炼油厂的供应来向中国施压。 然而,报告补充说,中国的反应仍然不明朗,因为中国已经建立了相当可观的石油储备,并且可能从美国将军事重心转向中东的战略中获益。 加拿大皇家银行(RBC)警告称,对伊朗实施封锁将比以往在委内瑞拉采取的行动更为复杂,并可能引发德黑兰对地区能源基础设施的报复性打击。 该报告强调,伊朗支持的伊拉克民兵组织是一个被忽视的威胁,并指出他们涉嫌参与了近期对科威特和沙特阿拉伯关键基础设施的袭击。 这些袭击包括破坏东西输油管道,凸显了除海上中断之外的更广泛的地区风险,并引发了人们对关键能源系统韧性的担忧。 尽管市场正在密切关注胡塞武装的行动升级,但加拿大皇家银行表示,如果伊拉克民兵在谈判破裂和封锁言论升级后加大行动力度,市场情绪可能会发生更剧烈的变化。 该行重申,冲突持续时间仍然是影响油价的关键因素,尽管美国领导层的表态已显著影响了短期市场预期。 加拿大皇家银行指出,尽管现货市场供应紧张,交易员难以找到短期供应缓解措施,但白宫的沟通仍有助于抑制油价,尽管市场面临诸多干扰。 如果封锁措施得以实施,分析师预计现货市场和纸币市场之间的联系将更加紧密,随着供应限制的日益凸显,价格波动可能会加剧。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.